Brief: Codiak Presents Preclinical Data Demonstrating Its Pan Beta-Coronavirus Vaccine Elicits Broad Protective Immunity Against Known Variants Of Sars-Cov-2 And Related Sarbecoviruses
12/10/2022 13:09
Oct 12 (Reuters) - Codiak BioSciences, Inc. CDAK.O :
* CODIAK PRESENTS PRECLINICAL DATA DEMONSTRATING ITS PAN
BETA-CORONAVIRUS VACCINE ELICITS BROAD PROTECTIVE IMMUNITY
AGAINST KNOWN VARIANTS OF SARS-COV-2 AND RELATED SARBECOVIRUSES
* CODIAK BIOSCIENCES - DATA SUPPORT ADVANCEMENT OF CODIAK'S
ENGINEERED EXOSOME BIVALENT VACCINE CANDIDATE TOWARD
IND-ENABLING STUDIES
Source text for Eikon: ID:nGNX6sGG3q
Further company coverage: CDAK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Codiak BioSciences,.
See all newsBrief: Codiak Biosciences Notice From Listing Qualifications Department Of Nasdaq Trading Of Co's Common Stock To Be Suspended At Opening Of Business On April 5
U.S. STOCKS ON THE MOVE-Energy firms, crypto stocks, Walt Disney
U.S. STOCKS ON THE MOVE-Cyclerion, banks, Jounce Therapeutics
U.S. STOCKS ON THE MOVE-Tesla, BrainStorm, Pinterest
Codiak BioSciences down after co files for Chapter 11 bankruptcy